Scientists test new eczema Drug's hidden effects on common pills
NCT ID NCT05891119
Summary
This small, early-stage study aimed to understand how a new drug for moderate-to-severe eczema (rocatinlimab) might change how the body processes other common medications. It involved 21 adults with eczema to measure drug levels in the blood when taken alone and together. The main goal was to check for safety and potential interactions, not to test how well the drug treats eczema symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accel Research Sites (ACR)
DeLand, Florida, 32720-3134, United States
-
Axis Clinicals, LCC
Dilworth, Minnesota, 56529, United States
-
DermDox Dermatology Centers, PC - Camp Hill
Camp Hill, Pennsylvania, 17011, United States
-
DermDox Dermatology Centers, PC - Sugarloaf
Nashville, Tennessee, 37203-1632, United States
-
Direct Helpers Research Center (DHRC)
Hialeah, Florida, 33012-3618, United States
-
Velocity Clinical Research -Spartanburg
Spartanburg, South Carolina, 29303-4225, United States
-
Velocity Clinical Research, North Hollywood
North Hollywood, California, 91606-1570, United States
Conditions
Explore the condition pages connected to this study.